Close Menu

Oxford Nanopore

Oxford Nanopore Technologies was founded in 2005 to develop an electronic, single molecule sensing system based on nanopore science. The company now has more than 250 employees from multiple disciplines including nanopore science, molecular biology and applications, informatics, engineering, electronics, manufacturing and commercialization. Oxford Nanopore's instruments MinIon, PromethIon, and GridIon are adaptable for the analysis of DNA, RNA, proteins, small molecules and other types of molecule.

Oxford Nanopore Facts

  • CEO: Gordon Sanghera
  • Website: www.nanoporetech.com
  • Ticker symbol: Privately held
  • Headquarters: Oxford, UK
  • Number of employees: 250+

The approach, which is developed for both Illumina and nanopore sequencing, had high sensitivity and specificity for identifying bacteria and fungi.

Investors in the round included International Holdings Company (IHC), based in Abu Dhabi, United Arab Emirates, and RPMI Railpen, a UK pension fund.

The initiative will build up pathogen sequencing capacity through investment from the Gates Foundation, Microsoft, Illumina, and Oxford Nanopore.

Oxford Nanopore said it is rolling out the LamPore test globally, initially in the UK, Germany, Switzerland, and the United Arab Emirates.

At its annual GPU conference this week, Nvidia said it is teaming with Oxford Nanopore, GSK, AstraZeneca, and PetaGene to advance bioinformatics and drug discovery.

A clinical evaluation of LamPore, expected to be CE marked shortly, called it promising for high-throughput testing but recommended a more streamlined workflow.

The nanopore sequencing-based test is designed to both diagnose SARS-CoV-2 infection, as well as monitor mutations that may affect efforts to combat the virus.

Under the non-exclusive deal, Oxford Nanopore can include the technology, which targets long DNA fragments, in its nanopore sequencing products.

The funding will be used to start a new trial to assess the benefits of repeat population testing, expand existing trials, and increase PCR-based testing capacity.

Pages

Nature News writes that viral genomic surveillance in the US faces systemic issues.

President Joe Biden is seeking an increase in federal spending, including higher budgets for the National Institutes of Health and Centers for Disease Control and Prevention.

A small, early-stage trial of a combination therapy for brain cancer reports favorable responses in two patients, according to the Guardian.

In PLOS this week: sex-stratified genome-wide association study of chronic pain, sequencing data from Indigenous Mexican groups, and more.